What is claimed is:

- 1. A pharmaceutical liposomal formulation for photodynamic therapy comprising a liposomal bilayer which consists substantially of phospholipids, and a therapeutically effective amount of a non-polar photosensitizer.
- 2. The liposomal formulation according to claim 1, wherein said phospholipids are selected from the group consisting of dipalmitoyl phosphatidyl choline, dipalmitoyl phosphatidyl glycerol, poly (ethylene glycol)-linked phospholipids and combinations of these three materials.
- 3. The liposomal formulation according to claim 1 wherein said photosensitizer is a porphyrin macrocycle photosensitizer.
- 4. The liposomal formulation according to claim 1 wherein said porphyrin macrocycle photosensitizer is selected from the group consisting of deuteroporphyrin, etioporphyrin, protoporphyrin, hematoporphyrin, pheophorbide and their di- and tetra-hydroporphyrin derivatives.
- 5. The liposomal formulation according to claim 1, which has been freeze dried, further comprising one or more monosaccharides or polyalcohols, and wherein the freeze dried formulation, upon addition of a suitable aqueous vehicle, forms liposomes containing a therapeutically effective amount of the non-polar photosensitizer within the liposomal bilayer.
- 6. The liposomal formulation according to claim 5 wherein said monosaccharide is selected from the group consisting of glucose and fructose.
- 7. The liposomal formulation according to claim 5 wherein said polyalcohol is selected from the group consisting of inositol and mannitol.
- 8. The liposomal formulation according to claim 5 wherein the concentration ratio of monosaccharide to phospholipid is between 1:2 and 1:12.
- 9. The liposomal formulation according to claim 5 wherein the concentration ratio of polyalcohol to phospholipid is between 1:2 and 1:12.
- 10. The liposomal formulation according to claim 5, reconstituted with an aqueous fluid for pharmaceutical administration.

- 11. The liposomal formulation according to claim 1 wherein the therapeutically effective concentration of the photosensitizer is from 0.0001 to 0.15 percent w/v.
- 12. The liposomal formulation according to claim 5 wherein the therapeutically effective concentration of the photosensitizer is from 0.0001 to 0.15 percent w/v.
- 13. The liposomal formulation according to claim 1 further comprising a component selected from the group consisting of butylated hydroxytoluene, ascorbic palmitate, and combinations of these two.
- 14. The liposomal formulation according to claim 5 further comprising a component selected from the group consisting of butylated hydroxytoluene, ascorbic palmitate, and combinations of these two.
- 15. The liposomal formulation according to claim 1 wherein the formulation further comprises at least one additional pharmaceutically active substance, especially polar, suitable to have some beneficial effect in a preselected therapy.
- 16. The liposomal formulation according to claim 5 wherein the formulation further comprises at least one additional pharmaceutically active substance, especially polar, suitable to have some beneficial effect in a preselected therapy.